DURECT Corp (OQ:DRRX)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 10240 Bubb Road CUPERTINO CA 95014 |
| Tel: | 1-646-3782928 |
| Website: | https://www.durect.com |
| IR: | See website |
| Key People | ||
| James E. Brown President, Chief Executive Officer, Director | Timothy M. Papp Chief Financial Officer, Company Secretary | Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance | Norman L. Sussman Chief Medical Officer |
| Business Overview |
| DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, DURECT Corp revenues decreased 56% to $8.5M. Net loss decreased 22% to $27.6M. Revenues reflect Europe segment decrease of 80% to $2.3M, Japan segment decrease of 62% to $559K. Lower net loss reflects Other Research and development decrease of 21% to $28.2M (expense), Selling and general decrease of 11% to $13M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.55 to -$1.05. |
| Employees: | 58 as of Mar 26, 2024 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $15.41M as of Dec 31, 2023 |
| Annual revenue (TTM): | $8.55M as of Dec 31, 2023 |
| EBITDA (TTM): | -$36.85M as of Dec 31, 2023 |
| Net annual income (TTM): | -$27.62M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$34.47M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 31,035,981 as of Mar 26, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.